NCT02574598 MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients Status COMPLETED Phase PHASE2
NCT02574078 A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) Status COMPLETED Phase PHASE1/PHASE2
NCT02568033 Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer Status UNKNOWN Phase EARLY_PHASE1
NCT02565901 Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT02564263 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Status COMPLETED Phase PHASE3
NCT02560051 Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer Status TERMINATED Phase PHASE2
NCT02551055 MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Status TERMINATED Phase PHASE1
NCT02549677 Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer Status COMPLETED Phase PHASE4
NCT02547987 Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02536495 Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer Status WITHDRAWN Phase PHASE1/PHASE2
NCT02531737 Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer Status COMPLETED Phase PHASE2
NCT02524275 Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Status TERMINATED Phase PHASE2
NCT02516670 Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer Status TERMINATED Phase PHASE2
NCT02514681 A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer Status COMPLETED Phase PHASE3
NCT02513342 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Status UNKNOWN Phase PHASE4
NCT02511132 A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Status COMPLETED Phase PHASE2
NCT02510781 A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs Status UNKNOWN Phase PHASE2
NCT02509286 Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02508246 WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck Status COMPLETED Phase PHASE1
NCT02495896 Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1